| Business Summary | | Allos
Therapeutics,
Inc.
is
a
pharmaceutical
company
focused
on
developing
and
commercializing
small
molecule
drugs,
initially
for
improving
cancer
treatments.
The
Company's
lead
product
candidate
is
RSR13,
a
synthetic
small
molecule
that
increases
the
release
of
oxygen
from
hemoglobin,
the
oxygen-carrying
protein
contained
within
red
blood
cells.
RSR13
may
be
used
to
improve
existing
cancer
treatments,
and
treat
many
diseases
and
clinical
conditions
attributed
to
or
aggravated
by
oxygen
deprivation,
or
hypoxia. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Allos
Therapeutics
is
a
pharmaceutical
company
focused
on
developing
and
commercializing
innovative
small
molecule
drugs,
initially
for
improving
cancer
treatments.
For
the
six
months
ended
6/30/01,
the
company
reported
no
revenue.
Net
loss
fell
35%
to
$9.6
million.
Results
reflect
lower
amortization
of
deferred
stock
compensation
expenses
and
the
absence
of
a
$7.6
million
stock
compensation
expense
resulting
from
the
forgiveness
of
notes
receivable. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Stephen Hoffman, Ph.D., M.D., 46 Pres,
CEO, Director | $391K | Michael Hart, 48 Sr.
VP, Operations, CFO | 287K | Michael Gerber, M.D., 48 Sr.
VP, Clinical Devel. and Regulatory Affairs | 356K | Markus Herzig, 56 VP
of Regulatory Affairs | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|